Gilead Sciences (GILD) Tops Q3 EPS by 38c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Gilead Sciences Announces Third Quarter 2022 Financial Results
October 27, 2022 4:01 PM EDTProduct Sales Excluding Veklury Increased 11% Year-Over-Year to $6.1 billion
Biktarvy Sales Increased 22% Year-Over-Year to $2.8 billion
Oncology Sales Increased 79% Year-Over-Year to $578 million
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2022.
Chairman and Chief Executive Officer of Gilead Sciences, Daniel ODay said: This was another very strong quarter across the business. In HIV, treatment and prevention markets continue to grow with further share gains for Biktarvy... More
